バイブントリキュラー・インペラ・サポートで救われた健康な若年成人におけるフルミナント・インフルーエンスA筋膜炎:症例報告
Ahmad Jalil1, Fatima Rajab2, Maheen Zaidi1
1Internal Medicine, Baptist Memorial Hospital-North Mississippi, Oxford, USA.
Cureus
|September 5, 2025
まとめ
インフルエンザAによるフルミナント心筋炎は重度の心不全を引き起こす可能性があります. Impella装置による早期の 循環器のサポートは 若い患者を成功裏に安定させ 迅速な回復につながり 潜在的な遺伝的傾向を強調しました
科学分野:
- 心臓病科
- 感染症
- クリティカル ケア 医療
背景:
- フルミナント心筋炎は希少で生命を脅かすインフルエンザAの合併症です.
- 急性双心筋不全と心臓発作性ショックに 急速に進行する可能性があります
- 重度の心臓機能障害は高度な治療戦略を必要とします.
研究 の 目的:
- インフルエンザAに二次的な発熱性心筋炎を呈する.
- 双面的なインペラ 機械的循環支援 (MCS) の有効性を強調する.
- 重度の心筋炎における遺伝的傾向の潜在的な役割について議論する.
主な方法:
- インフルエンザA誘発性 fulminant myocarditisの若い患者の症例報告
- 右側と左側の両方のImpella装置の機械的循環支援の適用
- MCS中のエジェクション分数を含む心臓機能の監視
主要な成果:
- 急性双心筋不全と心臓ショックの安定化に成功しました
- インペラを投与した数日後,エジェクション分子が有意に改善した.
- 早期のMCSによる 患者さんの回復が顕著です
結論:
- フルミナント心筋炎の管理には,早期に積極的な循環器のサポートが不可欠です.
- インペラ装置は,重度の心臓機能障害の場合に有効です.
- ウイルス誘発性心筋炎の遺伝的可能性を示唆する.
関連する概念動画
Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Myocarditis IV: Nursing Management
24
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
24
Myocarditis I: Introduction
28
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
28
Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Myocarditis II: Clinical Features and Diagnostic Tests
20
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
20
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21


